Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Health Ever Bio-Tech Co., Ltd.
This open-label extension study is designed to further assess the long-term safety and efficacy of MCS-2. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for another 40 weeks of MCS-2 treatment at the optimal dose selected after the phase 2b part of MCS-2-US-a. Subjects are limited to those who are currently not being treated medically for BPH or LUTS.
Age
40–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Subject has completed 12 weeks of treatment under the protocol MCS-2-US-a.
Subject is able to understand and willing to conform to the study procedures and has signed the informed consent form for participation in this extension study.
You may not be if
Subject has severe LUTS at the last visit under the protocol MCS-2-US-a.
Subject is considered ineligible for the study by the investigator(s).
